Preventing chlamydia and reinfection
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Prevention here has three parts that work: barriers, screening, and making sure partners are actually treated. Only the last one explains most reinfections.
There is also a newer tool, doxy-PEP, with a specific evidence base and a specific recommended group, and it is worth being precise about both.
Related pages: Chlamydia
The bottom line
- Previous infection gives no immunity.
- Condoms reduce transmission substantially when used consistently.
- Doxy-PEP reduces bacterial STIs in the groups where it has been studied.
- Reinfection is common and is usually from an untreated partner.
- The long-term effect of doxy-PEP on antimicrobial resistance and the microbiome.
- Whether doxy-PEP benefits cisgender women, where the one trial did not show efficacy.
The story, step by step
- 1. Barriers ()
- 2. Screening ()
- 3. Doxy-PEP ()
- 4. Reinfection ()
What the evidence labels mean
What they cover, honestly
What happens
Condoms and dams, with their real-world limits.
What the research shows
- External and internal condoms, latex or polyurethane, used from start to finish of every act of vaginal or anal sex, substantially reduce transmission.
- Real-world effectiveness is lower than laboratory effectiveness, almost entirely because of inconsistent use rather than failure of the condom.
- Water-based or silicone-based lubricant reduces breakage. Oil-based products, including petroleum jelly and lotions, destroy latex.
- Oral sex transmits chlamydia to and from the throat. Unlubricated condoms for fellatio and dams or cut-open condoms for cunnilingus and anilingus reduce it, and almost nobody uses them.
- Cover shared sex toys with a fresh condom for each person, or wash them between uses.
- Barriers also cover gonorrhea, trichomoniasis, HIV and pregnancy, which is why they remain relevant even for people using other prevention.
Why it matters
Condoms work when used. The honest framing is that the gap between efficacy and effectiveness is behavioural, not technical.
What's still uncertain
- Precise real-world effectiveness figures, which depend heavily on how consistency is measured.
Read more
- CDC: ChlamydiaGovernment
- CDC: STI screening recommendationsGovernment
- MedlinePlus: Chlamydia infectionsGovernment
Next: Screening
The part that does the heavy lifting
What happens
Why testing counts as prevention.
What the research shows
- Because most infections are silent, screening is what finds them before they are passed on or cause damage.
- Annual screening for sexually active women under 25; more often with new or multiple partners.
- Multi-site screening every 3 to 6 months for gay and bisexual men and other men who have sex with men, for people on HIV PrEP, and for people living with HIV.
- Screening at the first prenatal visit, with retesting later in pregnancy for those at continuing risk.
- Asking for the right sites to be tested is part of this. Urine alone misses rectal and throat infection.
- There is no vaccine for chlamydia, and having had it provides no immunity. Several vaccine candidates are in early trials.
Why it matters
Screening prevents transmission the way treatment does: by removing a source that nobody knew was there.
What's still uncertain
- Whether current screening programmes have reduced pelvic inflammatory disease at population level, which is debated.
Read more
- USPSTF: Screening for chlamydia and gonorrheaGovernment
- CDC: STI screening recommendationsGovernment
- CDC: ChlamydiaGovernment
Next: Doxy-PEP
Who it is for, precisely
What happens
A newer tool with a narrow evidence base.
What the research shows
- Doxy-PEP means taking a single 200 mg dose of doxycycline within 72 hours after condomless sex, not more than once in 24 hours.
- In three large randomized trials in men who have sex with men and transgender women, it substantially reduced chlamydia and syphilis, with a smaller effect on gonorrhea.
- The CDC recommends counselling about doxy-PEP for men who have sex with men and transgender women who have had syphilis, chlamydia or gonorrhea diagnosed in the past 12 months, and offering a prescription after shared decision-making.
- A trial in cisgender women in Kenya did not demonstrate efficacy, likely related to adherence, and the CDC makes no recommendation for that group. This is a gap in the evidence rather than a finding that it cannot work.
- People using doxy-PEP should have STI testing at the sites of exposure at baseline and every 3 to 6 months, with the ongoing need reassessed at the same intervals.
- The open question is resistance and the effect on the microbiome from repeated intermittent dosing, which has not been studied over the long term. Doxy-PEP is also irrelevant to trichomoniasis, which is a parasite.
- Side effects are the same as any doxycycline: sun sensitivity, stomach upset and the risk of oesophageal irritation if taken without water.
Why it matters
This is a real tool with real limits, and the limits are about which groups it has been shown to work in rather than about whether it works at all.
What's still uncertain
- Long-term resistance consequences, which is the main reason it is targeted rather than offered broadly.
Read more
- CDC: Clinical guidelines on doxycycline postexposure prophylaxis, 2024Government
- CDC: ChlamydiaGovernment
- CDC: STI treatment guidelines, chlamydial infectionsGovernment
Next: Reinfection
Partners, and the 3-month test
What happens
Why it comes back, and how to stop it.
What the research shows
- Reinfection within months is common, and the usual source is a partner who was never treated or was treated after you resumed sex.
- All partners from the past 60 days are treated at the same time as you, not afterwards.
- No sex of any kind until 7 days after single-dose treatment or after the full 7-day course, and until all partners have finished theirs. The clock runs from whoever finishes last.
- Retest at 3 months after treatment, whether or not symptoms came back and whether or not partners were treated. This is a reinfection check rather than a test of cure.
- Repeat infections carry a higher risk of pelvic inflammatory disease and tubal damage than a first infection, which is the reason this matters beyond the inconvenience.
- If you are reinfected more than once despite treating partners, that is a reason to revisit which sites were tested and whether something else is present.
Why it matters
Nearly all of the prevention failure in chlamydia happens at the partner treatment step rather than at the barrier or screening steps.
What's still uncertain
- How much repeat infection raises the risk of tubal damage, which is estimated from cohort studies.
Read more
- CDC: STI treatment guidelines, chlamydial infectionsGovernment
- CDC: Expedited partner therapyGovernment
- CDC: ChlamydiaGovernment